source
- CVS obesity drug deal puts Lilly on equal footing with NovoThe agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.BioPharma Dive · 2mo ago↗ source
- BioMarin drug acquired in buyout misses goal in rare disease studyTested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.BioPharma Dive · 2mo ago↗ source
- A migraine drugmaker heads to the public markets through reverse mergerMentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.